According to the recent study the Middle Eastern and North African active pharmaceutical ingredient (API) market is projected to reach an estimated $5.0 billion by 2030 from $3.2 billion in 2023, at a CAGR of 5.0% from 2023 to 2030. Growth in this market is primarily driven by pharmaceutical production and research and development of new drugs.
A more than 150 page report to understand trends, opportunities and forecast in Middle Eastern and North African active pharmaceutical ingredient (API) market by synthesis type (synthetic chemical, biotech and biologics, plant extracts, fermentation, and others), manufacturer type (captive API and merchant API), therapeutic area (cardiology, oncology, neurology, ophthalmology, orthopedics, pulmonology, aliment, anti-inflammatory, and others), product form (liquid API and powder API), molecule type (large molecule and small molecule), and drug type (branded, generic, and over-the-counter).
Lucintel forecasts that synthetic chemical will remain the largest segment over the forecast period due to continuous research and development activities and growing demand of synthetic chemical APIs in therapeutic areas.
Within this market, cardiology will remain the largest therapeutic area segment over the forecast period due to increasing cardiovascular diseases and increase in geriatric population.
Download report by clicking on Middle Eastern and North African active pharmaceutical ingredient (API) market
copyright, Teva Pharmaceutical, GSK, Sun Pharmaceutical, Novartis, Aurobindo, Merck& Co., BASF, Julphar, and AbbVie are the major suppliers in the Middle Eastern and North African active pharmaceutical ingredient (API) providers.
This unique research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or write us at [email protected]
About Lucintel
At Lucintel, we offer solutions for you growth through game changer ideas and robust market & unmet needs analysis. We are based in Dallas, TX and have been a trusted advisor for 1,000+ clients for over 20 years. We are quoted in several publications like the Wall Street Journal, ZACKS, and the Financial Times.
Contact:
Roy Almaguer
Lucintel
Dallas, Texas, USA
Email: [email protected]
Tel. +1 972.636.5056
Explore Our Latest Publications
Ring Doughnut Market
Stem Cell Research Antibody Market
Lead Counterweight Market
Sheet Molding Compound Market
Indian Composites Market
UK Composites Market